FDA Approves GADOBUTROL — Fresenius Kabi USA, LLC

# FDA Approves Fresenius Kabi's Generic Gadobutrol, Expanding MRI Contrast Agent Competition Fresenius Kabi USA, LLC has received FDA approval for its generic gadobutrol formulation, an intravenous MRI contrast agent that is expected to increase price competition in the diagnostic imaging market and improve patient access to this widely used medical imaging tool. The approval of this generic alternative could significantly reduce costs for healthcare systems and patients requiring magnetic resonance imaging procedures.